Zur Hauptnavigation wechseln Zur Suche wechseln Zum Hauptinhalt wechseln

Telomere length identifies two different prognostic subgroups among VH-unmutated B-cell chronic lymphocytic leukemia patients

  • I. Ricca*
  • , A. Rocci
  • , D. Drandi
  • , R. Francese
  • , M. Compagno
  • , C. Lobetti Bodoni
  • , F. De Marco
  • , M. Astolfi
  • , L. Monitillo
  • , S. Vallet
  • , R. Calvi
  • , F. Ficara
  • , P. Omedè
  • , R. Rosato
  • , A. Gallamini
  • , C. Marinone
  • , L. Bergui
  • , M. Boccadoro
  • , C. Tarella
  • , M. Ladetto
  • *Korrespondierende/r Autor/-in für diese Arbeit

Publikation: Beitrag in Fachzeitschrift (peer-reviewed) › Artikel in Fachzeitschrift

Abstract

Some evidences suggest that telomere restriction fragment length (TRF-L) is an effective indicator of histopathogenesis in B-cell tumors. As histopathogenesis is relevant for B-cell chronic lymphocytic leukemia (B-CLL) prognosis, TRF-L was assessed by Southern blot in 201 patients and compared to variable immunoglobulin heave chain gene mutational status (VH-MS) and to other known prognostic features. Overall survival (OS), time to first treatment (TTFT) and progression-free survival (PFS) were evaluated. Our results indicate the following: (1) TRF-L is heterogeneous among B-CLL patients (median 6014bp range 1465-16 762); (2) TRF-L correlates to VH-MS (r2>0.1994, P=0;0.0001) with VH-mutated patients showing long and VH-unmutated short telomeres; however, 41% of VH-unmutated and 5% of VH-mutated patients did not show this correlation and were thus defined as 'discordant'; (3) TRF-L effectively predicts outcome in terms of TTFT, PFS and OS; (4) VH-unmutated discordant patients have a better clinical outcome than VH-unmutated concordant patients (OS P=0;0.01, PFS P=0;0.05) and similar to that of VH-mutated patients (OS, PFS PNS). Compared to VH-unmutated concordant patients, VH-unmutated discordant patients showed no peculiarity in their immunoglobulin rearrangement nor in their flow cytometry or fluorescence in situ hybridization profile. In conclusion, TRF-L can be helpful to refine prognostication of B-CLL patients, particularly those with a VH-unmutated immunoglobulin sequence.

OriginalspracheEnglisch
Seiten (von - bis)697-705
Seitenumfang9
FachzeitschriftLeukemia
Jahrgang21
Ausgabenummer4
DOIs
PublikationsstatusVeröffentlicht - Apr. 2007
Extern publiziertJa

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

  1. SDG 3 – Gute Gesundheit und Wohlergehen
    SDG 3 – Gute Gesundheit und Wohlergehen

ASJC Scopus Sachgebiete

  • Hämatologie
  • Onkologie
  • Krebsforschung

Fingerprint

Untersuchen Sie die Forschungsthemen von „Telomere length identifies two different prognostic subgroups among VH-unmutated B-cell chronic lymphocytic leukemia patients“. Zusammen bilden sie einen einzigartigen Fingerprint.

Dieses zitieren